Background: Novasomes (Novs) are a novel lipid-based drug delivery system (LBDDS) for enhanced drug delivery. Those systems are composed of surface active agents (SAA) and free fatty acids (FFA) that self-assemble into spherical bilayer structures to encapsulate a variety of therapeutic drugs. Novs have been extensively studied as drug carriers, including antifungals, antibiotics, anti- inflammatory, and anticancer drugs. They approved better solubility and permeability, greater therapeutic efficacy, and diminished side effects when compared to free drug formulations. Aims of this review: This review provides a thorough outlook, including novasomal constituents, development techniques, advantages and disadvantages, variant characterizations, routes of administration, pharmacological applications, and future prospects in the field of novasomal research.
mortaga, Y., & Elnady, R. (2025). A Comprehensive Review on Novasomes As Lipid-Based Drug Carriers. Sinai International Scientific Journal, 2(1), 21-35. doi: 10.21608/sisj.2025.442481
MLA
Yasmin Ismail mortaga; Rana E. Elnady. "A Comprehensive Review on Novasomes As Lipid-Based Drug Carriers", Sinai International Scientific Journal, 2, 1, 2025, 21-35. doi: 10.21608/sisj.2025.442481
HARVARD
mortaga, Y., Elnady, R. (2025). 'A Comprehensive Review on Novasomes As Lipid-Based Drug Carriers', Sinai International Scientific Journal, 2(1), pp. 21-35. doi: 10.21608/sisj.2025.442481
VANCOUVER
mortaga, Y., Elnady, R. A Comprehensive Review on Novasomes As Lipid-Based Drug Carriers. Sinai International Scientific Journal, 2025; 2(1): 21-35. doi: 10.21608/sisj.2025.442481
)
View on SCiNiTO